Across the modern healthcare landscape, some of the most dangerous diseases are not always the ones that arrive suddenly or dramatically. Increasingly, physicians and medical researchers are sounding alarms about chronic illnesses capable of progressing quietly for years while patients remain completely unaware significant damage is already occurring inside the body.
Few diseases represent that reality more clearly than IgA Nephropathy.
Known medically as IgAN and sometimes referred to as Berger’s Disease, the rare autoimmune kidney disorder often develops gradually and silently, with symptoms that can easily be overlooked, misinterpreted, or dismissed until substantial kidney damage has already taken place. For many patients, diagnosis does not arrive until the disease has advanced significantly, creating long-term complications that can permanently alter quality of life.
Now, one New Jersey-based organization is attempting to change that reality on a national scale.
The Wall Township-headquartered IgA Nephropathy Foundation is marking its 22nd anniversary by launching the first major nationwide awareness initiative in the organization’s history — a large-scale public service campaign titled “Are You IgAN Aware?” that is designed to dramatically increase visibility surrounding one of the most misunderstood and underrecognized kidney diseases in modern medicine.
Officially unveiled May 1, 2026, the campaign represents a major escalation not only for the foundation itself, but for the broader movement surrounding rare kidney disease advocacy across the United States.
What makes the initiative especially significant is its scope.
Rather than relying exclusively on traditional nonprofit outreach channels, the Foundation is pushing aggressively into mainstream public visibility through digital media, social campaigns, connected television advertising, live public events, and one of the most culturally recognizable platforms in American life: Major League Baseball.
Under the companion theme “Strike Out IgAN,” the campaign is expanding into 22 MLB ballparks throughout the United States and Canada during the month of May, bringing awareness events, educational outreach, patient advocacy gatherings, and public-facing medical information directly into some of the country’s largest public venues.
The approach reflects a growing reality within modern healthcare advocacy.
Awareness campaigns increasingly succeed not simply by distributing information, but by embedding themselves inside existing cultural spaces where large audiences already gather naturally. Sports partnerships, live events, digital streaming visibility, and highly shareable media campaigns now play enormous roles in shaping public health awareness efforts, particularly for diseases that historically operated outside mainstream public conversation.
For the IgA Nephropathy Foundation, that visibility matters enormously because IgAN remains widely misunderstood despite its potentially devastating long-term consequences.
The disease occurs when an antibody known as immunoglobulin A builds up inside the kidneys, causing inflammation that gradually damages the organs’ filtering systems. Over time, the condition can lead to progressive kidney deterioration, chronic kidney disease, hypertension, and, in severe cases, eventual kidney failure requiring dialysis or transplantation.
One of the greatest dangers surrounding IgAN is how quietly it can progress.
Many early warning signs appear deceptively minor or intermittent. Patients may experience cola-colored urine, foamy urine, elevated blood pressure, swelling, fatigue, or subtle changes in kidney function that initially seem unrelated to a larger systemic illness. In other cases, symptoms remain virtually invisible for years before diagnosis finally occurs during unrelated medical testing.
That delayed recognition has become one of the central issues driving the Foundation’s new awareness push.
The “Are You IgAN Aware?” campaign specifically emphasizes the importance of early testing, encouraging individuals to pay closer attention to potential kidney-related symptoms while also reinforcing the value of routine blood and urine screenings capable of detecting early abnormalities before irreversible damage develops.
Importantly, the campaign also reflects a much broader transformation currently happening throughout the rare disease advocacy world itself.
For years, many rare disease organizations operated with limited public visibility and relatively small research ecosystems. But advances in digital outreach, patient registries, biotech research partnerships, and online advocacy communities have dramatically expanded the ability of nonprofit foundations to organize globally, recruit participants for clinical studies, and accelerate research collaboration.
The IgA Nephropathy Foundation is positioning itself directly inside that evolving healthcare landscape.
A major component of the new campaign centers around increasing participation in the organization’s newly launched IgAN Hope Patient Registry, an international clinical data initiative designed to help researchers gather larger pools of patient information capable of accelerating treatment development and future therapeutic research.
Patient registries have become increasingly critical in modern rare disease research because many conditions simply do not affect enough people in concentrated geographic areas for traditional research recruitment methods to work efficiently. Large-scale international databases help researchers identify trends, treatment outcomes, disease progression patterns, and potential clinical trial candidates much more rapidly.
For IgAN patients specifically, those advancements carry enormous emotional weight.
Many individuals diagnosed with rare autoimmune kidney disorders often describe long periods of uncertainty, isolation, delayed diagnosis, and difficulty finding accessible information about the disease itself. National awareness campaigns help reduce that isolation by creating greater public recognition and encouraging broader conversation around symptoms, diagnosis, and long-term treatment pathways.
The Foundation’s decision to center the campaign around baseball also carries symbolic significance beyond visibility alone.
Baseball remains one of the few truly intergenerational public spaces in American culture where families, communities, healthcare initiatives, and large-scale public engagement naturally intersect. Stadium awareness nights and public advocacy partnerships have increasingly become powerful vehicles for medical organizations seeking to humanize complex diseases in environments that feel accessible and communal rather than clinical or intimidating.
Inside those ballparks this month, the “Strike Out IgAN” campaign will feature educational materials, patient advocacy gatherings, awareness graphics displayed on stadium video boards, and direct outreach efforts designed to connect with audiences who may have never previously heard of the disease.
That level of exposure could prove especially important given how many kidney diseases remain substantially underdiagnosed nationwide.
Healthcare professionals across the nephrology community have increasingly warned that many chronic kidney conditions continue progressing unnoticed because early symptoms often appear manageable or easily dismissed. Public education surrounding warning signs and preventative testing has therefore become one of the most important tools available in reducing long-term disease progression.
For New Jersey specifically, the campaign also highlights the state’s growing influence within healthcare advocacy, nonprofit medical leadership, and patient-centered public health initiatives.
Organizations based throughout the Garden State continue playing major roles in research support, healthcare policy, medical technology, and disease-awareness outreach that extends far beyond state borders. The IgA Nephropathy Foundation’s expansion into a nationally visible campaign reinforces how organizations rooted in New Jersey are increasingly helping shape broader national conversations surrounding healthcare access, education, and chronic disease awareness.
The timing of the initiative also aligns with a larger shift happening throughout modern medicine itself.
Patients today are more proactive, digitally connected, and information-driven than at any point in healthcare history. Advocacy organizations increasingly serve not only as support networks, but as educational platforms, research facilitators, policy voices, and large-scale public awareness engines capable of influencing everything from early diagnosis rates to funding priorities.
The “Are You IgAN Aware?” campaign reflects that evolution directly.
It is not simply an anniversary celebration for the Foundation.
It is an attempt to fundamentally change how people recognize, discuss, and respond to a disease that too often remains invisible until major damage has already occurred.
For Explore New Jersey readers following developments in healthcare, medical advocacy, and public wellness initiatives across the state, the launch of this campaign stands as an important reminder that some of the most impactful healthcare movements begin not inside hospital systems or pharmaceutical boardrooms, but inside community-driven organizations determined to make overlooked diseases impossible to ignore.
And this month, from Wall Township to Major League ballparks across North America, the IgA Nephropathy Foundation is attempting to do exactly that.
